A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery

Trial Profile

A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Teprasiran (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Sponsors Quark Pharmaceuticals
  • Most Recent Events

    • 27 Jul 2017 According to a Quark Pharmaceuticals media release, data from this study will be submitted for presentation at an upcoming medical congress.
    • 27 Jul 2017 Results published in a Quark Pharmaceuticals Media Release.
    • 27 Jul 2017 Status changed from active, no longer recruiting to completed, according to a Quark Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top